Free tool
FAERS Monitor: Gvoke Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212097 or its brand name (Gvoke Kit, Glucagon). Reports on generic versions are filed under their own applications.
Reports
16
Serious
7
44% of reports
Hospitalization
3
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose decreased3
- constipation2
- death2
- dizziness2
- screaming2
- abdominal pain1
- abdominal pain upper1
- aphasia1
- arthralgia1
- atrial fibrillation1
- blood creatinine increased1
- blood pressure systolic decreased1
- blood urea increased1
- bradycardia1
- breast cancer metastatic1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2014 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,143 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| screaming | 2 | 412.9 | 112.9 | 462 |
| blood pressure systolic decreased | 1 | 289.0 | 43.3 | 71 |
| breast cancer metastatic | 1 | 122.5 | 18.4 | 30 |
| blood glucose decreasedSignal | 3 | 82.1 | 29.6 | 167 |
| blood urea increased | 1 | 78.5 | 11.8 | 19 |
| aphasia | 1 | 43.5 | 6.5 | 10 |
| bradycardia | 1 | 24.8 | 3.7 | 5 |
| blood creatinine increased | 1 | 20.1 | 3.0 | 4 |
| atrial fibrillation | 1 | 13.5 | 2.0 | 2 |
| constipation | 2 | 12.1 | 3.3 | 11 |
| abdominal pain upper | 1 | 6.4 | 1.0 | 1 |
| abdominal pain | 1 | 5.7 | 0.8 | 1 |
| dizziness | 2 | 5.3 | 1.4 | 3 |
| arthralgia | 1 | 3.2 | 0.5 | 0 |
| death | 2 | 3.1 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.